Antiangiogenic Drugs for Chemotherapy of Bladder Tumours

Rocchetti, Romina; Talevi, Simona; Margiotta, Chiara; Calza, R; Corallini, Alfredo; Possati, L

doi:10.1159/000088950

Cited by 7 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An understanding of the cellular and molecular basis of tumor angiogenesis, and a means of measuring its extent, are therefore important for clinicians who diagnose and treat cancer by whatever modalities. We would like to direct the readers to an excellent review of antiangiogenic drugs for chemotherapeutic treatment of bladder tumors which has been published in Chemotherapy [150] .…”

Section: Glut1 As a Marker Of Hypoxiamentioning

confidence: 99%

Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics

2007

View full text Add to dashboard Cite

Cancer cells require a steady source of metabolic energy in order to continue their uncontrolled growth and proliferation. Accelerated glycolysis is one of the biochemical characteristics of cancer cells. Recent work indicates that glucose transport and metabolism are essential for the posttreatment survival of tumor cells, leading to poor prognosis. Glycolytic breakdown of glucose is preceded by the transport of glucose across the cell membrane, a rate-limiting process mediated by facilitative glucose transporter proteins belonging to the facilitative glucose transporter/solute carrier GLUT/SLC2A family. Tumors frequently show overexpression of GLUTs, especially the hypoxia-responsive GLUT1 and GLUT3 proteins. There are also studies that have reported associations between GLUT expression and proliferative indices, whilst others suggest that GLUT expression may be of prognostic significance. In this article we revisit Warburg’s original hypothesis and review the recent clinical and basic research on the expression of GLUT family members in human cancers and in cell lines derived from human tumors. We also explore the links between hypoxia-induced genes, glucose transporters and angiogenic factors. Hypoxic tumors are significantly more malignant, metastatic, radio- and chemoresistant and have a poor prognosis. With the discovery the oxygen-sensitive transcription factor hypoxia-inducible factor (HIF-1) has come a new understanding of the molecular link between hypoxia and deregulated glucose metabolism. HIF-1 induces a number of genes integral to angiogenesis, e.g. vascular endothelial growth factor (VEGF), a process intimately involved with metastatic spread. This knowledge may enhance existing chemotherapeutic strategies so that treatment can be more rationally applied and personalized for cancer patients.

show abstract

Section: Glut1 As a Marker Of Hypoxiamentioning

confidence: 99%

Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics

2007

View full text Add to dashboard Cite

show abstract

“…showed that anti-VEGF drugs have a potential benefit in bladder tumors that express VEGF. [27] However, anti-VEGF drugs in bladder tumor therapy are considered investigational yet.…”

Section: Discussionmentioning

confidence: 99%

Assessment of angiogenic factor, vascular endothelial growth factor, serum and urine level changes in superficial bladder tumor immunotherapy by intravesical Bacillus Calmette-Guerin

Kerigh¹,

Bahrami²,

Shamsa³

et al. 2010

Urol Ann

View full text Add to dashboard Cite

Background and Aim:Bladder tumor is one of the most common genitourinary tumors. Management of non-muscle invasive (NMI) bladder tumors is primarily by transurethral resection (TURBT) followed by intravesical immunotherapy or chemotherapy. Bacillus Calmette-Guerin (BCG) is the most effective adjuvant therapy in NMI bladder tumor. Since angiogenesis is an essential factor in solid tumor progression and vascular endothelial growth factor (VEGF) is an important factor in angiogenesis, the aim of this study is the assessment of angiogenic factor, VEGF, serum and urine level changes in superficial bladder tumor immunotherapy by intravesical BCG.Materials and Methods:A total of 23 patients with bladder transitional cell carcinoma (TCC) in stage Ta/T1 or carcinoma insitu (CIS), low or high grade, which passed a 2-4 week period from TURBT participated in this study. Blood and urine samples were obtained at first and sixth sessions before instillation of BCG. Enzyme-linked immunosorbent assay (ELISA) method was used to obtain VEGF level in samples.Results:Urine and serum VEGF levels did not change significantly before and after BCG therapy. Changes in VEGF level were significantly different neither in low grade against high grade tumors nor in stage T1 against stage Ta tumors. A significant difference in VEGF level was seen between low grade and high grade tumors in serum after BCG therapy (P=0.007); but not in urine samples.Conclusion:Although intravesical BCG possesses anti-angiogenic activity, it seems that it exerts its effect through pathways other than VEGF, especially in low grade tumors.

show abstract

“…ABT-510 is a peptide mimetic of thrombospondin-1, designed for blocking angiogenesis [29,30]. Dalteparin targets heparin associated modulation of angiogenesis [31][32][33]. Previously we have described series of flavonoids as potential anti-angiogenic, anti-cancer and antioxidant agents.…”

Section: Introductionmentioning

confidence: 99%

Flavonoids as a scaffold for development of novel anti-angiogenic agents: An experimental and computational enquiry

Gacche

Meshram

Shegokar

et al. 2015

Archives of Biochemistry and Biophysics

View full text Add to dashboard Cite

Antiangiogenic Drugs for Chemotherapy of Bladder Tumours

Cited by 7 publications

References 21 publications

Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics

Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics

Assessment of angiogenic factor, vascular endothelial growth factor, serum and urine level changes in superficial bladder tumor immunotherapy by intravesical Bacillus Calmette-Guerin

Flavonoids as a scaffold for development of novel anti-angiogenic agents: An experimental and computational enquiry

Contact Info

Product

Resources

About